WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC 5th levels

List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.

ATC codeATC level nameDeadline for objection to temporary codesImplementation in ATC/DDD index
A01AB24octenidineFinal2023
A01AB25oxytetracyclineFinal2023
A01AC04prednisoloneFinal2023
A02BX15teprenoneFinal2023
A03FA10acotiamide01.09.20222023
A05BA10phospholipidsFinal2023
A06AX09elobixibatFinal2023
A08AA51phentermine and topiramateFinal2023
A10BX16 tirzepatide01.09.20222023
A10BX17carfloglitazar01.09.20222023
A10BX18dorzagliatin01.09.20222023
A16AB23cipaglucosidase alfaFinal2023
A16AB24pegzilarginase01.09.20222023
A16AB25olipudase alfa01.09.20222023
A16AX21elivaldogene autotemcelFinal2023
A16AX22tiomolibdic acidFinal2023
B06AX04mitapivatFinal2023
C01EB24mavacamtenFinal2023
C02KX54macitentan and tadalafil01.09.20222023
C09BB13benazepril and amlodipine 01.09.20222023
C09DX08telmisartan, amlodipine and hydrochlorothiazide01.09.20222023
C10BX19atorvastatin, amlodipine and candesartanFinal2023
D01AC21neticonazoleFinal2023
D01AC22lanoconazoleFinal2023
D01AE25liranaftateFinal2023
D11AH09ruxolitinibFinal2023
G01AF21 tinidazole01.09.20222023
G02CX06fezolinetant01.09.20222023
G04BD14imidafenacinFinal2023
G04CA55doxazosin and finasterideFinal2023
G04CB51finasteride and tadalafil01.09.20222023
H01AC09lonapegsomatropin01.09.20222023
H01CC53elagolix, estradiol and norethisterone01.09.20222023
H02CA04levoketoconazole01.09.20222023
H03AA51levothyroxine sodium and iodine compoundsFinal2023
H04AA02dasiglucagon Final2023
J01RA16 cefixime and azithromycin01.09.20222023
J02AX07ibrexafungerpFinal2023
J02AX08rezafungin acetate01.09.20222023
J04BA50dapsone and rifampicin01.09.20222023
J04BA51dapsone, rifampicin and clofazimine01.09.20222023
J05AB18molnupiravir01.09.20222023
J05AE30nirmatrelvir and ritonavir01.09.20222023
J06BD04ansuvimabFinal2023
J06BD05sotrovimabFinal2023
J06BD06regdanvimabFinal2023
J06BD07casirivimab and imdevimabFinal2023
J06BD08nirsevimabFinal2023
J07AX01leptospira vaccinesFinal2023
J07BN01 1)covid-19, RNA-based vaccineFinal2023
J07BN02 1)covid-19, viral vector, non-replicatingFinal2023
J07BN03 1)covid-19, inactivated virusFinal2023
J07BN04 1)covid-19, protein subunit 01.09.20222023
J07XA01malaria vaccines01.09.20222023
L01CD51paclitaxel and encequidarFinal2023
L01EB09lazertinibFinal2023
L01EB10mobocertinibFinal2023
L01EB11aumolertinib01.09.20222023
L01EG04sirolimus01.09.20222023
L01EM05parsaclisib Final2023
L01EX24surufatinibFinal2023
L01EX25umbralisib01.09.20222023
L01FD06margetuximabFinal2023
L01FX19sabatolimabFinal2023
L01FX20tremelimumabFinal2023
L01FX21naxitamabFinal2023
L01FX22loncastuximab tesirine01.09.20222023
L01FX23tisotumab vedotin01.09.20222023
L01XL05ciltacabtagene autoleucel01.09.20222023
L01XL06brexucabtagene autoleucel 01.09.20222023
L01XL07idecabtagene vicleucel01.09.20222023
L01XX75tebentafuspFinal2023
L01XX77adagrasib01.09.20222023
L01XY03nivolumab and relatlimabFinal2023
L03AA18efbemalenograstim alfa01.09.20222023
L04AA57ublituximabFinal2023
L04AA58efgartigimod alfaFinal2023
L04AA59avacopan01.09.20222023
L04AC23olokizumab01.09.20222023
M03BX53pridinol, combinationsFinal2023
M05BX08menatetrenoneFinal2023
N04BA07foslevodopa and decarboxylase inhibitorFinal2023
N05AH53olanzapine and samidorphanFinal2023
N06AX29brexanolone01.09.20222023
N06BA15dexmethylphenidate and serdexmethylphenidateFinal2023
N07XX18vutrisiranFinal2023
R02AD05ambroxol01.09.20222023
R06AA61dimenhydrinate, combinations01.09.20222023
S01AA29 dibekacinFinal2023
S01AA31cefmenoximeFinal2023
S01AE09tosufloxacinFinal2023
S01KX02trypan blue01.09.20222023
S01LA09faricimabFinal2023
S01XA28varenicline01.09.20222023
S01XA29sepofarsen01.09.20222023
S02AA17fosfomycinFinal2023
S02AA18cefmenoxime Final2023
S03CA07methylprednisolone and antiinfectivesFinal2023
V04CX10pafolacianine01.09.20222023
V08CA12gadopiclenolFinal2023
V09AX07flortaucipir (18F) 01.09.20222023
V09IX15copper (64Cu) dotatateFinal2023
V09IX16piflufolastat (18)Final2023
V09IX17fluorine (18) PSMA-1007Final2023
V10XX05lutetium (177Lu) vipivotide tetraxetanFinal2023
1) New ATC 5th level to be included in new ATC 4th level J07BN Covid-19 vaccines the Index 2023

Last updated: 2022-05-04